| [1] |
Coffelt SB,Kersten K,Doornebal CW, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis [J]. Nature, 2015, 522(7556): 345-348.
|
| [2] |
Kitamura T,Qian BZ,Pollard JW. Immune cell promotion of metastasis [J]. Nat Rev Immunol, 2015, 15(2): 73-86.
|
| [3] |
Denkert C,Loibl S,Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer [J]. J Clin Oncol, 2010, 28(1): 105-113.
|
| [4] |
Denkert C,Von Minckwitz G,Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers [J]. J Clin Oncol, 2015, 33(9): 983-991.
|
| [5] |
Martens A,Wistuba-Hamprecht K,Geukes Foppen M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab [J]. Clin Cancer Res, 2016, 22(12): 2908-2918.
|
| [6] |
Jacquelot N,Roberti MP,Enot DP, et al. Immunophenotyping of stage Ⅲ melanoma reveals parameters associated with patient prognosis [J]. J Invest Dermatol, 2016, 136(5): 994-1001.
|
| [7] |
Martens A,Wistuba-Hamprecht K,Yuan J, et al. Increases in absolute lymphocytes and circulating CD4＋ and CD8＋ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab [J]. Clin Cancer Res, 2016, 22(19): 4848-4858.
|
| [8] |
Bandura DR,Baranov VI,Ornatsky OI, et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry [J]. Anal Chem, 2009, 81(16): 6813-6822.
|
| [9] |
Liyanage UK,Moore TT,Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma [J]. J Immunol, 2002, 169(5): 2756-2761.
|
| [10] |
Wolf AM,Wolf D,Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients [J]. Clin Cancer Res, 2003, 9(2): 606-612.
|
| [11] |
Ichihara F,Kono K,Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers [J]. Clin Cancer Res, 2003, 9(12): 4404-4408.
|
| [12] |
Ormandy LA,Hillemann T,Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma [J]. Cancer Res, 2005, 65(6): 2457-2464.
|
| [13] |
Miller AM,Lundberg K,Ozenci V, et al. CD4＋CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients [J]. J Immunol, 2006, 177(10): 7398-7405.
|
| [14] |
Sade-Feldman M,Kanterman J,Klieger Y, et al. Clinical significance of circulating CD33＋CD11b＋HLA-DR- myeloid cells in patients with stage Ⅳ melanoma treated with ipilimumab [J]. Clin Cancer Res, 2016, 22(23): 5661-5672.
|
| [15] |
Kao SC,Pavlakis N,Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy [J]. Clin Cancer Res, 2010, 16(23): 5805-5813.
|
| [16] |
Verronese E,Delgado A,Valladeau-Guilemond J, et al. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay [J]. Oncoimmunology, 2016, 5(3): e1100791.
|
| [17] |
Chen Y,Chen K,Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study [J]. BMC Cancer, 2016, 16(5): 320-326.
|
| [18] |
Templeton AJ,Mcnamara MG,Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis [J]. J Natl Cancer Inst, 2014, 106(6): 124-132.
|
| [19] |
Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation [J]. Cell, 2011, 144(5): 646-674.
|
| [20] |
Farren MR,Mace TA,Geyer S, et al. Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic cancer [J]. Clin Cancer Res, 2016, 22(10): 2565-2574.
|
| [21] |
Yao X,Ahmadzadeh M,Lu YC, et al. Levels of peripheral CD4(＋)FoxP3(＋) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer [J]. Blood, 2012, 119(24): 5688-5696.
|
| [22] |
Merlo A,Casalini P,Carcangiu ML, et al. FOXP3 expression and overall survival in breast cancer [J]. J Clin Oncol, 2009, 27(11): 1746-1752.
|
| [23] |
Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity [J]. Cancer Immunol Immunother, 2010, 59(10): 1593-1600.
|
| [24] |
Zheng H,Liu X,Zhang J, et al. Expression of PD-1 on CD4＋ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer [J]. Oncotarget, 2016, 7(35): 56 233-56 240.
|
| [25] |
Hutloff A,Dittrich AM,Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 [J]. Nature, 1999, 397(6716): 263-266.
|
| [26] |
Liakou CI,Kamat A,Tang DN, et al. CTLA-4 blockade increases IFNgamma-producing CD4＋ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients [J]. Proc Natl Acad Sci U S A, 2008, 105(39): 14 987-14 992.
|
| [27] |
Carthon BC,Wolchok JD,Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial [J]. Clin Cancer Res, 2010, 16(10): 2861-2871.
|
| [28] |
姜玲博,袁洋,刘毅, 等. 循环肿瘤细胞预测乳腺癌骨转移进展一例[J/CD]. 中华乳腺病杂志(电子版), 2011, 5(5): 640-642.
|
| [29] |
崇梅红,肇毅,王水, 等. 可手术乳腺癌循环肿瘤细胞与原发肿瘤临床病理特征的关系[J/CD]. 中华乳腺病杂志(电子版), 2013, 7(2): 80-85.
|